Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma

OBJECTIVES: Therapy of patients with relapsed and refractory classic Hodgkin lymphoma (r/r cHL) after PD-1 inhibitors failure remains an unresolved issue. The aim of this study was to evaluate the efficacy and safety of the combination of nivolumab with brentuximab vedotin (Nivo + BV) after nivoluma...

Descripción completa

Detalles Bibliográficos
Autores principales: Fedorova, Liudmila V., Lepik, Kirill V., Volkov, Nikita P., Kotselyabina, Polina V., Borzenkova, Evgenia S., Popova, Marina O., Beynarovich, Anastasia V., Baykov, Vadim V., Kozlov, Andrey V., Moiseev, Ivan S., Mikhailova, Natalia B., Kulagin, Alexander D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619646/
https://www.ncbi.nlm.nih.gov/pubmed/34826011
http://dx.doi.org/10.1007/s10147-021-02085-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619646/
https://www.ncbi.nlm.nih.gov/pubmed/34826011
http://dx.doi.org/10.1007/s10147-021-02085-6

Ejemplares similares